Skip to content

Meals and Grazing Study

Meals and Grazing Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02548026
Acronym
MAGS
Enrollment
15
Registered
2015-09-14
Start date
2011-01-31
Completion date
2012-06-30
Last updated
2015-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

meal frequency, eating frequency, ingestive frequency, positive energy balance, satiety, appetite, hunger

Brief summary

The purpose of this study was to determine the effects of low vs. high eating frequency (EF) on biomarkers of health and subjective appetite.

Detailed description

Observational studies have demonstrated an inverse relationship between eating frequency (EF), obesity, and other markers for disease risk. It has been suggested that consumption of several small, frequent meals may influence physiological mechanisms, reducing the risk for disease and lowering appetite. Participants in this randomized crossover study completed two intervention phases lasting three weeks each: one of low eating frequency (low-EF; 3 eating occasions/day) and one of high eating frequency (high-EF; 8 eating occasions/day). Fasting C-reactive protein, insulin-like growth factor, and leptin were measured at baseline and endpoint of each phase and an optional subjective appetite testing session lasting four hours was offered at the endpoint of each phase. During appetite testing sessions, participants consumed an amount of food equal in total energy and macronutrient content at either one occasion at 8:00 am (low-EF condition) or spread evenly over two smaller eating occasions at 8:00 am and 10:30 am (high-EF condition). Ratings of hunger, desire to eat, fullness, thirst, and nausea were made every 30 minutes using paper-and-pencil semi-anchored 100-mm Visual Analog Scales. A composite appetite score was calculated as the mean of hunger, desire to eat, and 100-fullness. The generalized estimating equation modification of linear regression was used to compare fasting plasma biomarkers and mean ratings of subjective appetite.

Interventions

BEHAVIORALHigh Eating Frequency (High EF)

Free-living participants complete a 21-day high eating frequency (high EF) Phase in which they consume all daily energy at 8 eating occasions.

BEHAVIORALLow Eating Frequency (Low EF)

Free-living participants complete a 21-day low eating frequency (low EF) Phase in which they consume all daily energy at 3 eating occasions.

Sponsors

Fred Hutchinson Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Participants will be overweight and obese (BMI 25 and over) males and females ages 18-50 years. * Participants must be willing to report to FHCRC on 5 occasions (initial screening appointment + 4 testing sessions) * Participants must be willing to provide a 7-day food record for analysis prior to Phase 1 and Phase 2 of the study * Participants must be willing to follow diet protocol during Phase 1 of the study * Participants must be willing to undergo 4 blood draws

Exclusion criteria

* Non-diabetic (self-report) * Non-smokers (self-report) * Not following a diet to gain or lose weight (self-report) * Normal cholesterol (self-report) * Normal blood pressure (self-report) * Not currently taking any medication (self-report) * Not pregnant or nursing (self-report and verification by DEXA) * Not athletes in training (self-report)

Design outcomes

Primary

MeasureTime frameDescription
Inflammatory biomarkers in high vs. low eating frequency conditions3 weeksInflammatory biomarkers in high vs. low eating frequency conditions

Secondary

MeasureTime frameDescription
Subjective appetite in high vs. low eating frequency conditions4 hoursSubjective appetite as reported using visual analog scale in high vs. low eating frequency conditions

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026